Brexpiprazole II: Antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 3, 2014, Pages 605-614

  Maeda, Kenji ^a   Lerdrup, Linda ^c   Sugino, Haruhiko ^a   Akazawa, Hitomi ^a   Amada, Naoki ^a   McQuade, Robert D ^b   Stensbøl, Tine Bryan ^c   Bundgaard, Christoffer ^c   Arnt, Jørn ^c   Kikuchi, Tetsuro ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; APOMORPHINE; ARIPIPRAZOLE; BREXPIPRAZOLE; BUSPIRONE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PHENCYCLIDINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; VOLINANSERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; AVOIDANCE BEHAVIOR; BEHAVIOR DISORDER; CATALEPSY; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; EYELID REFLEX; HAPLORHINI; HYPERACTIVITY; MALE; NONHUMAN; PATTERN RECOGNITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STEREOTYPY;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; COGNITION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MACACA FASCICULARIS; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; SEROTONIN; TREATMENT OUTCOME;

EID: 84904981694     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.213819     Document Type: Article

References (52)

1. Andrews JS, Jansen JH, Linders S, Princen A, and Broekkamp CLE (1995) Performance of four different rat strains in the autoshaping, two-object discrimination, and swim maze tests of learning and memory. Physiol Behav 57:785-790.
2. Arnt J (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283:55-62.
3. Arnt J, Bang-Andersen B, Dias R, and Bøgesø KP (2008) Strategies for pharmacotherapy of schizophrenia. Drugs Future 33:777-791 DOI: 10.1358/dof.2008.033.09.1236966.
4. Arnt J, Bøgesø KP, Hyttel J, and Meier E (1988) Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacol Toxicol 62:121-130.
5. Arnt J and Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
6. Blaxall HS, Murphy TJ, Baker JC, Ray C, and Bylund DB (1991) Characterization of the alpha-2C adrenergic receptor subtype in the opossum kidney and in the OK cell line. J Pharmacol Exp Ther 259:323-329.
7. Birrell JM and Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20:4320-4324.
8. Casey DE (1996) Side effect profiles of new antipsychotic agents. J Clin Psychiatry 57 (Suppl 11):40-45, discussion 46-52
9. Casey DE, Sands EE, Heisterberg J, and Yang HM (2008) Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl) 200:317-331.
10. Citrome L (2013) Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 9:193-206.
11. Costall B and Naylor RJ (1973) On the mode of action of apomorphine. Eur J Pharmacol 21:350-361.
12. Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, and Haddjeri N (2009) Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol 23:177-189.
13. 1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 22:2873-2884.
14. Elsworth JD, Lawrence MS, Roth RH, Taylor JR, Mailman RB, Nichols DE, Lewis MH, and Redmond DE, Jr (1991) D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J Pharmacol Exp Ther 259: 595-600.
15. Fleischhacker WW (2005) Aripiprazole. Expert Opin Pharmacother 6:2091-2101.
16. Goetghebeur P and Dias R (2009) Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following sub-chronic PCP administration in the rat - a back translational study. Psychophar-macology (Berl) 202:287-293.
17. Goetghebeur PJD, Lerdrup L, Sylvest A, and Dias R (2010) Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model. Psychopharmacology (Berl) 212:635-642.
18. Grayson B, Idris NF, and Neill JC (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184:31-38.
19. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330.
20. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, and Heaton RK, et al (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56:301-307.
21. Horiguchi M, Hannaway KE, Adelekun AE, Jayathilake K, and Meltzer HY (2012) Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. Neuropsychopharmacology 37:2175-2183.
22. Horiguchi M and Meltzer HY (2012) The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl) 221:205-215.
23. Idris N, Neill J, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, and Arnt J (2010) Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl) 208:23-36.
24. Karson CN (1983) Spontaneous eye-blink rates and dopaminergic systems. Brain 106:643-653.
25. Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, and Stewart M (2013) Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull 39:417-435.
26. Keefe RS and Harvey PD (2012) Cognitive impairment in schizophrenia. Handbook Exp Pharmacol 213:11-37.
27. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, and Morita S (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274:329-336.
28. Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, and Gyertyán I, et al. (2010) Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333:328-340.
29. Kleven MS and Koek W (1996) Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys. J Pharmacol Exp Ther 279:1211-1219.
30. Lapiz MDS and Morilak DA (2006) Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 137:1039-1049.
31. Laoutidis ZG and Luckhaus C (2014) 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. Int J Neuropsychopharmacol 17:823-832
32. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, and Mørk A, et al. (2014) Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:589-604.
33. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, and Kapur S (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164: 1411-1417.
34. Marcus MM, Wiker C, Frånberg O, Konradsson-Geuken A, Langlois X, Jardemark K, and Svensson TH (2010) Adjunctive α2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol 13:891-903.
35. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(2, Suppl)106S-115S.
36. Meltzer HY, Horiguchi M, and Massey BW (2011) The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 213:289-305.
37. Migler BM, Warawa EJ, and Malick JB (1993) Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology (Berl) 112:299-307.
38. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, and Nabeshima T (2009) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 202:315-328.
39. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, and Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128:419-432.
40. 1A receptor agonism in anti-psychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 11: 802-812.
41. Newman-Tancredi A, Cussac D, and Depoortere R (2007) Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 8:539-554.
42. 1A receptor properties. Psychopharmacology (Berl) 216:451-473.
43. Nikiforuk A, Kos T, Fijał K, Hołuj M, Rafa D, and Popik P (2013) Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS ONE 8:e66695.
44. Nikiforuk A and Popik P (2012) Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats. Psychopharmacology (Berl) 220:65-74.
45. Redrobe JP, Bull S, and Plath N (2010) Translational aspects of the novel object recognition task in rats abstinent following sub-chronic treatment with phency-clidine (PCP): effects of modafinil and relevance to cognitive deficits in schizophrenia. Front Psychiatry 1:146.
46. Rodefer JR, Nguyen TN, Karlsson JJ, and Arnt J (2008) Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33:2657-2666.
47. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
48. Sallinen J, Holappa J, Koivisto A, Kuokkanen K, Chapman H, Lehtimäki J, Piepponen P, Mijatovic J, Tanila H, and Virtanen R, et al. (2013) Pharmacological characterisation of a structurally novel α2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol 113:239-249.
49. Stahl SM (2001) Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 62:923-924.
50. Wong EH, Nikam SS, and Shahid M (2008) Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs 9:28-36.
51. 3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27:248-259.
52. Young JW, Powell SB, Risbrough V, Marston HM, and Geyer MA (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122:150-202.